Use of tranexamic acid in hip replacement operation to reduce bleeding

Role of tranexamic acid in controlling blood loss in total hip arthroplasty - nil

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/058278

Enrollment

Registered

2023-10-04

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Tranexamic acid: Tranexamic acid dose 15 mg/kg intravenous, once during operation, effect for 48 hours Intervention2: tranexamic acid: use of tranexamic acid to control blood loss dose

Eligibility

Inclusion criteria

Inclusion criteria: all unilateral total hip arthroplasty cases

Exclusion criteria

Exclusion criteria: history of coagulation or bleeding disorder history of dvt or pulmonary embolism hepatic or renal disease cardiovascular disease

Design outcomes

Primary

Measure	Time frame
prevent blood lossTimepoint: 48 hours	—

Secondary

Measure	Time frame
blood pressureTimepoint: 48 hours	—

Countries

India

Contacts

Public ContactManish singh chauhan

peoples college of medical science bhopal

lovelytabish@hotmail.com9407503442

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026